Over Half of Targetable NSCLC Patients Miss Out on Correct T

Most patients with advanced non–small cell lung cancer (NSCLC) have tumors with actionable mutations, but two thirds of them are not receiving targeted therapy owing to gaps in clinical practice.

Related Keywords

California , United States , Maryland , San Diego , Washington , La Jolla , Baltimore , Sandipp Patel , Janet Freeman , Julier Brahmer , Daryl Pritchard , University Of California , Drug Administration , Personalized Medicine Coalition , Janet Freeman Daily , Clinical Practice , Medscape Medical , Sidney Kimmel Comprehensive Cancer Center , Johns Hopkins , Personalized Medicine , Diaceutics Data Repository , Hispanic White , Lung Cancer , Ung Carcinoma , Ancer Lung , Biologic Therapy , Liquid Biopsy , Luid Biopsy , Luid Phase Biopsy , Cancer Blood Test , Ancer Saliva Test , Lood Biopsy , Erum Biopsy , Targeted Therapy , Genomics , Genomic Medicine , Edicine Genomic , Biomarker , Iological Marker , Small Cell Lung Cancer , Biopsy , Cancer , Alignant Neoplasia , Arcinoma , Coronavirus , 019 Novel Coronavirus , 019 Ncov , Uhan Coronavir ,